Apimeds Pharmaceuticals US, Inc
APUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $25,359 | $25,359 | $25,359 | $25,359 |
| - Cash | $3 | $410 | $6 | $171 |
| + Debt | $597 | $267 | $660 | $400 |
| Enterprise Value | $25,953 | $25,216 | $26,013 | $25,588 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,272 | -$740 | -$640 | -$1,019 |
| % Margin | – | – | – | – |
| Net Income | -$1,390 | -$778 | -$669 | -$1,026 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.11 | -0.061 | -0.053 | -0.081 |
| % Growth | -79.4% | -16.3% | 34.8% | – |
| Operating Cash Flow | -$734 | -$628 | -$448 | -$823 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$734 | -$628 | -$448 | -$823 |